Cryptococcosis: An emerging infectious disease of global public health importance (original) (raw)

Abstract

Cryptococcosis is an emerging deadly systemic disease caused by Cryptococcus, which is basidiomycetous, encapsulated yeast that occurs as a saprobe in nature. Only two species are known to cause disease from the genus Cryptococcus: Cryptococcus neoformans and Cryptococcus gattii. The source of infection is exogenous and the respiratory tract acts as the chief portal entry of fungus. The mode of disease getting from the contaminated environment is by inhalation of infectious fungal agent. An array of clinical spectrum of disease is reported in humans.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (26)

  1. Kourbeti IS, Mylonakis E. 1. Kourbeti IS, Mylonakis E. Fungal central nervous system infections: prevalence and diagnosis. Expert Rev Anti- infect. Ther. 2014 Feb; 12(2): 265-273.
  2. Christianson JC, Engber W, Andes D. Primary cutaneous cryptococcosis in immunocompetent and immunocompromised hosts. Med Mycol. 2003 Jan; 41(3): 177-88.
  3. Pal M, Dave P. Cryptococcosis: A global fungal zoonosis. Intas Polivet. 2006; 6: 412-20.
  4. Vercelli C, Peano A, Piovano G. Diagnostic and therapeutic management of Cryptococcosis in a kitten with practical considerations to veterinary pediatric therapeutic approach. Med Mycol Case Rep. 2021 Jun; 32: 61-3.
  5. Maziarz EK, Perfect JR. Cryptococcosis. Infectious Disease Clinics. 2016 Mar; 30(1): 179-206.
  6. Devi SJ, Schneerson R, Egan W, Ulrich TJ, Bryla D, Robbins JB, Bennett JE. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect. immun. 1991 Oct; 59(10): 3700-07.
  7. Mourad A, Perfect JR. The war on cryptococcosis: a review of the antifungal arsenal. Mem Inst Oswaldo Cruz 2018 Feb; 19(1); 113.
  8. Setianingrum F, Rautemaa-Richardson R, Denning DW. Pulmonary cryptococcosis: a review of pathobiology and clinical aspects. Medical mycology. 2019 Feb; 57(2): 133-50.
  9. Firacative C, Meyer W, Castañeda E. Cryptococcus neoformans and Cryptococcus gattii species complexes in Latin America: a map of molecular types, genotypic diversity, and antifungal susceptibility as reported by the Latin American Cryptococcal Study Group. J. Fungi. 2021 Apr 9; 7(4): 282.
  10. Suwatanapongched T, Sangsatra W, Boonsarngsuk V,et al. Clinical and radiologic manifestations of pulmonary cryptococcosis in immunocompetent patients and their outcomes after treatment. Diagn. Interv. Radiol. 2013 Nov; 19(6): 438.
  11. Kourbeti IS, Mylonakis E. Fungal central nervous system infections: prevalence and diagnosis. Expert Rev. Anti-infect. Ther. 2014 Feb; 12(2): 265-73.
  12. Lockhart SR, Iqbal N, Harris JR et al. DeBess E, Wohrle R, Marsden- Haug N, Vugia DJ. Cryptococcus gattii in the United States: Expert Rev Anti-infect Ther. 2013 Sep; 8(9): 747-57.
  13. Christianson JC, Engber W, Andes D. Primary cutaneous cryptococcosis in immunocompetent and immunocompromised hosts. Med Mycol. 2003 Jan; 41(3):177-88.
  14. Maziarz EK, Perfect JR. Cryptococcosis, Infect. Dis. Clin. 2016 Mar ;30(1): 179-206.
  15. Nyazika TK, Tatuene JK, Kenfak-Foguena. Epidemiology and aetiologies of cryptococcal meningitis in Africa, 1950-2017: protocol for a systematic review. BMJ open. 2018 Jul 1;8(7): 206-54.
  16. Pal M, Tesfaye S, Dave P. Cryptococcosis: An enigmatic mycosis of humans and animals. J Environ. Occup. Health. 2014; 3(1): 53-60.
  17. Pal M. Use of Pal's sunflower seed medium for an early diagnosis of cryptococcosis. The Antiseptic. 1997;95(5). Neuroscience. 2006; 142(4): 941-52.
  18. Pal M. Cryptococcus neoformans var. neoformans and Munia Birds Cryptococcus neofovmans var. neoformans bei Prachtfinken. Mycoses. 12 May; 32(5): 250-2.
  19. Chesdachai S, Rajasingham R,et al. Minimum inhibitory concentration distribution of fluconazole against cryptococcus species and the fluconazole exposure prediction model. In Open forum infect. dis 2019 oct; 6(10), 369-78
  20. World Health Organization. Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children.
  21. InGuidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children 2018.
  22. Arendash GW , Schleif W , Rezai-Zadeh K, et al. Caffeine protects
  23. Alzheimer's mice against cognitive impairment and reduces brain β- amyloid production. Neuroscience. 2006; 142(4): 941-52.
  24. Firacative C, Meyer W, Castañeda E. Cryptococcus neoformans and Cryptococcus gattii species complexes in Latin America: a map of molecular types, genotypic diversity, and antifungal susceptibility as reported by the Latin American Cryptococcal Study Group. J. Fungi. 2021 Apr 9; 7(4): 282.
  25. Vercelli C, Peano A, Piovano G. Diagnostic and therapeutic management of Cryptococcosis in a kitten with practical considerations to veterinary pediatric therapeutic approach. Med Mycol Case Rep. 2021 Jun; 32:61-3.
  26. Setianingrum F, Rautemaa-Richardson R, Denning DW. Pulmonary cryptococcosis: a review of pathobiology and clinical aspects. Medical mycology. 2019 Feb ;57(2): 133-50.